Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.
Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, Harke NN, Debus J, Koerber SA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Seibold P, Kristiansen G, Hadaschik B, Arsov C, Schimmöller L, Giesel FL, Antoch G, Makowski M, Wacker F, Schlemmer HP, Kaaks R, Albers P. Krilaviciute A, et al. Among authors: lakes j. Eur Urol Oncol. 2023 Dec;6(6):566-573. doi: 10.1016/j.euo.2023.09.008. Epub 2023 Oct 6. Eur Urol Oncol. 2023. PMID: 37806841
[PSA screening and molecular markers].
Lakes J, Arsov C. Lakes J, et al. Urologe A. 2019 May;58(5):486-493. doi: 10.1007/s00120-019-0900-y. Urologe A. 2019. PMID: 30874831 Review. German.
PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
Morawitz J, Kirchner J, Lakes J, Bruckmann NM, Mamlins E, Hiester A, Aissa J, Loberg C, Schimmöller L, Arsov C, Antke C, Albers P, Antoch G, Sawicki LM. Morawitz J, et al. Among authors: lakes j. Eur J Radiol. 2021 Mar;136:109556. doi: 10.1016/j.ejrad.2021.109556. Epub 2021 Jan 16. Eur J Radiol. 2021. PMID: 33485127
Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial.
Krilaviciute A, Albers P, Lakes J, Radtke JP, Herkommer K, Gschwend J, Peters I, Kuczyk M, Koerber SA, Debus J, Kristiansen G, Schimmöller L, Antoch G, Makowski M, Wacker F, Schlemmer H, Benner A, Giesel F, Siener R, Arsov C, Hadaschik B, Becker N, Kaaks R. Krilaviciute A, et al. Among authors: lakes j. Int J Cancer. 2023 Mar 1;152(5):854-864. doi: 10.1002/ijc.34295. Epub 2022 Oct 5. Int J Cancer. 2023. PMID: 36121664 Free article. Clinical Trial.
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Boschheidgen M, Albers P, Schlemmer HP, Hellms S, Bonekamp D, Sauter A, Hadaschik B, Krilaviciute A, Radtke JP, Seibold P, Lakes J, Arsov C, Gschwend JE, Herkommer K, Makowski M, Kuczyk MA, Wacker F, Harke N, Debus J, Körber SA, Benner A, Kristiansen G, Giesel FL, Antoch G, Kaaks R, Becker N, Schimmöller L. Boschheidgen M, et al. Among authors: lakes j. Eur Urol. 2024 Feb;85(2):105-111. doi: 10.1016/j.eururo.2023.09.027. Epub 2023 Oct 18. Eur Urol. 2024. PMID: 37863727
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, Lakes J, Radtke JP, Kuczyk M, Harke NN, Debus J, Fink CA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Kristiansen G, Hadaschik B, Arsov C, Schimmöller L, Antoch G, Giesel FL, Makowski M, Wacker F, Schlemmer HP, Becker N, Albers P. Krilaviciute A, et al. Among authors: lakes j. Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.04.030. Online ahead of print. Eur Urol. 2024. PMID: 38749854 Free article.
15 results